Physician profile
John Robert Traverso
NPI 1235212614
$6,916.05
in general payments reported to CMS, 2019-2025
38 companies · $1,112 in 2025
The $1,112 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $690 · 2020: $252 · 2021: $226 · 2022: $201 · 2023: $1,716 · 2024: $2,720 · 2025: $1,112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,547.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,273.91 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $866.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $774.94 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $708.54 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $553.07 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Astellas Pharma US INC | $349.48 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $235.17 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $234.14 | 2024-2025 | Cologuard Collection Kit |
| Pfizer INC. | $163.84 | 2023-2025 | |
| Amgen INC. | $163.15 | 2023-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $162.89 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $141.78 | 2023-2025 | Jardiance, Tradjenta |
| Abbott Laboratories | $132.26 | 2021-2025 | Freestyle Libre 3 |
| Bausch Health US, LLC | $117.65 | 2023-2025 | Wellbutrin, Aplenzin |
| Lundbeck LLC | $106.31 | 2023-2024 | Rexulti |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Traverso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.